SCS Capital Management’s Generation Bio GBIO Stock Holding History

SCS Capital Management’s Portfolio GBIO Stock Details GBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-972	Closed	-$276K	–	43
2020 Q4	$276K	Buy	+972	New	+$312K	0.01%	43

Other funds holding GBIO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

SCS Capital Management's GBIO Position: Q1 2021 in Review

SCS Capital Management sold out of Generation Bio (GBIO) in Q1 2021, closing a stake of 972 shares — an estimated $276K sold.

SCS Capital Management first reported a position in GBIO in Q4 2020 and held it in 1 quarter. The position peaked at $276K in Q4 2020. 88 funds tracked by Wall St. Rank hold GBIO as of Q1 2021.

SCS Capital Management reported no remaining Generation Bio position as of Q1 2021 after selling out during the quarter.
SCS Capital Management sold 972 Generation Bio shares in Q1 2021, an estimated $276K.
SCS Capital Management first reported a position in Generation Bio in Q4 2020 and held it in 1 quarter.
SCS Capital Management's Generation Bio position peaked at $276K in Q4 2020.
88 funds tracked by Wall St. Rank held Generation Bio as of Q1 2021.

Based on SCS Capital Management's 13F filing for Q1 2021, filed 12 May 2021.